Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Erfonrilimab - Alphamab

Next Previous
Drug Profile

Erfonrilimab - Alphamab

Alternative Names: Anti-PD-L1 / CTLA-4 bispecific antibody; KN-046

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alphamab
  • Developer Beijing Cancer Hospital; InxMed; Jiangsu Alphamab Biopharmaceuticals; Peking University; Shanghai Pulmonary Hospital; Suzhou Kintor Pharmaceuticals; Weill Cornell Medical College; Zhejiang Raygene Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Thymic epithelial tumour
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer; Pancreatic cancer
  • Phase II/III Malignant thymoma
  • Phase II Colorectal cancer; Digestive system neoplasms; Gastric cancer; Liver cancer; Oesophageal cancer; Solid tumours
  • Phase I/II Triple negative breast cancer
  • No development reported Lymphoma

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease, Metastatic disease) in China (IV, Infusion)
  • 28 Jun 2025 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (IV, Infusion)
  • 09 Jan 2025 Jiangsu Alphamab Biopharmaceuticals in collaboration with Zhejiang Raygene Pharmaceuticals terminates phase IIa trial in Colorectal cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) in China (Parenteral), due to business operation strategy adjustment (NCT06834399)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top